Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ozenoxacin - Ferrer/Maruho

Drug Profile

Ozenoxacin - Ferrer/Maruho

Alternative Names: GF-001001-00; M-512101; M5120; OZANEX; T-3912; Xepi

Latest Information Update: 16 Apr 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Toyama Chemical
  • Developer Cipher Pharmaceuticals; Ferrer; Maruho
  • Class Antiacnes; Antibacterials; Cyclopropanes; Pyridines; Quinolones; Small molecules
  • Mechanism of Action DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Impetigo
  • Registered Acne vulgaris; Skin and soft tissue infections

Most Recent Events

  • 27 Sep 2018 Maruho completes a phase II trial for Acne vulgaris (Combination therapy, In adolescents, In adults) in Japan (Topical) (UMIN000024874)
  • 05 Mar 2018 Ozenoxacin sub-licensed to Cutanea Life Sciences from Medimetrix Pharmaceuticals in USA
  • 05 Mar 2018 Updated adverse events data from clinical trials in Impetigo released by Cutanea Life Sciences
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top